Aptose Biosciences Inc.
APTOFDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Virulizin®
Pancreatic Cancer
GTI-2040
Acute Myeloid Leukemia
Tuspetinib
Leukemia, Myeloid, Acute
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Virulizin® | Phase 3 | Pancreatic Cancer | - | - |
GTI-2040 | Phase 2 | Acute Myeloid Leukemia | - | - |
Tuspetinib | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Pancreatic Cancer
1 drug in this indication
Acute Myeloid Leukemia
1 drug in this indication
Leukemia, Myeloid, Acute
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aptose Biosciences Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Aptose Biosciences Inc.'s (APTOF) pipeline across Phase 3, Phase 2. Its lead program is Virulizin® (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aptose Biosciences Inc.'s next FDA catalyst?→
Aptose Biosciences Inc.'s (APTOF) next tracked catalyst is a Phase 2 expected November 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APTOF biotech catalysts?→
Add APTOF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aptose Biosciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.